BioMarin (BMRN) | Stock Overview & Key Data
BioMarin Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $151.75 on July 20, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| BioMarin BMRN | 10.37B Large-cap | 4.44% | 0.93% | -2.96% | -15.45% | -13.66% | -29.40% | -35.41% | -54.39% |
| Vertex VRTX | 114.06B Large-cap | 3.19% | 2.97% | -3.19% | 12.51% | 13.22% | -3.15% | 56.18% | 56.09% |
| Regeneron REGN | 55.27B Large-cap | 2.50% | 3.96% | -6.05% | -26.32% | -24.76% | -47.08% | -11.94% | -11.84% |
| Alnylam ALNY | 40.83B Large-cap | -0.60% | 6.62% | 39.14% | 37.37% | 38.74% | 32.22% | 117.66% | 104.57% |
| Royalty Pharma plc RPRX | 20.32B Large-cap | -1.22% | 6.59% | 14.70% | 36.67% | 38.00% | 41.68% | -15.34% | -23.66% |
| Insmed INSM | 20.02B Large-cap | -3.67% | 37.17% | 42.39% | 46.65% | 38.60% | 39.71% | 294.35% | 251.29% |
Ownership & Short Interest
BioMarin Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in BioMarin would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
In the last 52 weeks, BioMarin reached a high of $94.85 (on August 20, 2024) and a low of $52.93 (on April 9, 2025).
Curious about BioMarin's size and valuation? Its market capitalization stands at 10.37B. When it comes to valuation, the P/E ratio (trailing twelve months) is 20.03, and the forward P/E (looking ahead) is 18.09.
As for dividends, BioMarin isn't currently offering a significant yield, or that specific data isn't available right now.
When looking at BioMarin, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX114.06B Healthcare Biotechnology -3.15% 56.18% Regeneron
REGN55.27B Healthcare Biotechnology -47.08% -11.94% Alnylam
ALNY40.83B Healthcare Biotechnology 32.22% 117.66% Royalty Pharma plc
RPRX20.32B Healthcare Biotechnology 41.68% -15.34% Insmed
INSM20.02B Healthcare Biotechnology 39.71% 294.35% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
To get a sense of BioMarin's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 9.64%, the Debt to Equity ratio from the most recent quarter is 10.39, and its Gross Profit Margin stands at 79.66%.
Looking at BioMarin's growth, its revenue over the trailing twelve months (TTM) was $3B. Compared to the same quarter last year (YoY), quarterly revenue grew by 14.80%, and quarterly earnings saw a YoY growth of 109.40%.
Wondering who owns BioMarin stock? Company insiders (like executives and directors) hold about 0.85% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 98.97%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.